Refining endpoints in brain tumor clinical trials

Area of Science:

• Neuro-oncology
• Clinical Trials
• Neuroscience

Background:

• Advanced targeted therapies are improving outcomes for brain tumor patients.
• Traditional clinical trial endpoints like survival and radiographic response may not fully capture treatment benefits.
• Brain tumors often exhibit neurodegenerative characteristics, complicating the interpretation of standard endpoints.

Purpose of the Study:

• To highlight the limitations of current clinical trial endpoints in brain cancer.
• To advocate for the routine inclusion of neurocognitive assessments in clinical trials.
• To emphasize the importance of quality of life alongside survival in brain tumor treatment.

Main Methods:

• Review of current clinical trial endpoint standards in neuro-oncology.
• Analysis of the impact of neurocognitive decline on patient-reported outcomes.
• Discussion of the neurodegenerative aspects of brain malignancies.

Main Results:

• Standard endpoints (survival, progression-free survival, radiographic response) are inadequate for assessing clinical benefit in brain tumors.
• Prolonged survival or stable disease can be clinically meaningless if accompanied by significant neurocognitive decline.
• Neurocognitive function is a critical, yet often overlooked, measure of therapeutic success.

Conclusions:

• Neurocognitive assessment should be a standard component of brain tumor clinical trials.
• Integrating neurocognitive endpoints will provide a more comprehensive understanding of treatment efficacy.
• Prioritizing neurocognitive health alongside survival is essential for improving the quality of life for brain cancer patients.